相关实验视频

Updated: May 5, 2026

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

使用常见和罕见的遗传变异来治疗肌缩性侧面硬化症的药物重定向候选者

Zachary F Gerring^1,2,3, Oneil G Bhalala^1,4, Liam G Fearnley^1,3

¹Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.

Brain communications

|May 21, 2025

概括

对肌缩性侧面硬化症 (ALS) 的药物重新定位可以根据遗传风险来指导. 这项研究确定了B-Raf抑制剂和B维生素作为ALS患者的潜在治疗候选者,为治疗提供了新的途径.

科学领域:

神经科学是一个神经科学.
遗传学遗传学是一个
药理学药理学是指药理学的学科.

背景情况:

肌缩侧面硬化症 (ALS) 是一种进展性神经退行性疾病,治疗选择有限.
药物重新定位为ALS提供了更快的新疗法途径,但疾病异质性使候选人选择复杂化.
由于ALS遗传责任的多基因性质,这为识别广泛适用的药物重定向候选人提供了机会.

研究的目的:

利用ALS中常见和罕见的遗传风险变异来确定有前途的药物重定向候选人.
调查潜在的治疗点,包括B-Raf抑制剂和B-维生素相关化合物.

主要方法:

全基因组关联研究 (GWAS) 和SNP基因型数据分析用于常见的变异主导方法.
基于基因的定位和功能测试,以确定信号通路.
全基因组测序和罕见变异负担测试用于罕见变异主导的方法.
具有致病变异的ALS衍生细胞系的转录组分析 (C9orf72,SOD1,FUS,TARDBP).

主要成果:

常见变异分析涉及通过B-Raf抑制剂降低调节的线粒素激活蛋白激酶信号.
罕见变异分析优先考虑了与维生素B相关的候选物质,如可巴胺和尼亚.
转录组数据表明B-Raf抑制剂与C9orf72载体相关,而B-维生素与SOD1载体相关.

结论:

整合常见和罕见的遗传风险数据对于确定异质ALS中有效的药物重新定位策略至关重要.
B-Raf抑制剂和B-维生素作为ALS患者特定遗传特征的治疗候选物具有前景.
需要进一步的临床前和临床研究来验证这些优先考虑的化合物用于ALS治疗.

关键词:

毒品的重新使用.整个外体组的关联研究研究.全基因组关联研究研究.运动神经元疾病运动神经元疾病干细胞是干细胞的组成部分.

更多相关视频

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Published on: February 12, 2015

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...